Armistice Capital LLC Trims Holdings in DENTSPLY SIRONA Inc. $XRAY

Key Points

• Armistice Capital LLC reduced its stake in DENTSPLY SIRONA Inc. by 14.3% during the first quarter, now holding approximately 3 million shares valued at about $44.8 million.
• Other institutional investors also increased or initiated positions in DENTSPLY SIRONA, with 95.70% of the stock held by hedge funds and institutional investors.
• DENTSPLY SIRONA reported earnings of $0.52 per share for the last quarter, surpassing analyst estimates and setting a FY 2025 EPS guidance of $1.800 to $2.000.

Armistice Capital LLC trimmed its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 14.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,000,148 shares of the medical instruments supplier's stock after selling 499,480 shares during the quarter. DENTSPLY SIRONA comprises 0.7% of Armistice Capital LLC's holdings, making the stock its 28th largest position. Armistice Capital LLC owned approximately 1.51% of DENTSPLY SIRONA worth $44,822,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Colonial Trust Co SC purchased a new position in DENTSPLY SIRONA during the fourth quarter valued at approximately $26,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in DENTSPLY SIRONA during the first quarter valued at approximately $25,000. Brooklyn Investment Group purchased a new position in DENTSPLY SIRONA during the first quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd raised its position in DENTSPLY SIRONA by 8,003.6% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,269 shares of the medical instruments supplier's stock valued at $34,000 after acquiring an additional 2,241 shares in the last quarter. Finally, Allworth Financial LP raised its position in DENTSPLY SIRONA by 175.8% during the first quarter. Allworth Financial LP now owns 3,949 shares of the medical instruments supplier's stock valued at $54,000 after acquiring an additional 2,517 shares in the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Stock Performance

Shares of NASDAQ:XRAY opened at $14.30 on Friday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.69 and a quick ratio of 1.11. The business's 50 day moving average price is $15.15 and its 200-day moving average price is $15.35. The firm has a market capitalization of $2.85 billion, a PE ratio of -3.02, a P/E/G ratio of 0.89 and a beta of 0.94. DENTSPLY SIRONA Inc. has a 1 year low of $12.16 and a 1 year high of $27.48.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.50 by $0.02. The firm had revenue of $936.00 million for the quarter, compared to analyst estimates of $929.67 million. DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%.The business's revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.49 earnings per share. DENTSPLY SIRONA has set its FY 2025 guidance at 1.800-2.000 EPS. As a group, equities research analysts expect that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 10th. Stockholders of record on Friday, September 26th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 4.5%. DENTSPLY SIRONA's payout ratio is currently -13.50%.

Analysts Set New Price Targets

Several brokerages recently weighed in on XRAY. Barrington Research reduced their price target on DENTSPLY SIRONA from $21.00 to $18.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. Wells Fargo & Company reduced their price target on DENTSPLY SIRONA from $16.00 to $15.00 and set an "equal weight" rating for the company in a research report on Friday, August 8th. Stifel Nicolaus dropped their price objective on DENTSPLY SIRONA from $19.00 to $17.00 and set a "hold" rating on the stock in a report on Friday, August 8th. Wall Street Zen lowered DENTSPLY SIRONA from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Needham & Company LLC reissued a "hold" rating on shares of DENTSPLY SIRONA in a report on Monday, July 21st. Two analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $18.64.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.